(Q36408751)

14 August 2017

1 reference

title

Ranolazine, a novel agent for chronic stable angina (English)

1 reference

14 August 2017

Sarah M Gaffney

1

1 reference

PubMed ID

16506355

14 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

26

1 reference

14 August 2017

1

1 reference

14 August 2017

135-142

1 reference

Energy metabolism in the hypertrophied heart

14 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Ranolazine: a novel metabolic modulator for the treatment of angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Metabolic manipulation in ischaemic heart disease, a novel approach to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Current and future treatment strategies for refractory angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Ranolazine as add-on therapy for patients with severe chronic angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Ranolazine and other antianginal therapies in the era of the drug-eluting stent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

Ranolazine as add-on therapy for patients with severe chronic angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.135

10.1592/PHCO.2006.26.1.135

21 January 2018

Identifiers

DOI

1 reference

release_uzsqgo7ezzby5lp7l6d3fbi3pq

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uzsqgo7ezzby5lp7l6d3fbi3pq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16506355

1 reference

PubMed ID

16506355